Navigation Links
The John Theurer Cancer Center to host Seventh Annual Neuro-Oncology Symposium

HACKENSACK, N.J. (May 9, 2011) The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education (CME) conference will present the latest neuro-oncology trends by leaders in the field.

"For the seventh consecutive year, we are able to bring together leaders in neuro-oncology to provide insights on the latest advancements in the neuro-oncology field," said Viswanathan Rajaraman, M.D., Co-Chief of Neuro-Oncology at the John Theurer Cancer Center. "We are proud to bring together a group of highly esteemed oncologists to our new comprehensive cancer center to discuss the latest trends in our field."

Topics to be discussed at the Seventh Annual Neuro-Oncology Symposium: Controversies in Neuro-Oncology and Para Neoplastic Syndromes Affecting the CNS include controversies in radiosurgery and whole brain radiotherapy in metastatic brain tumors, management of para neoplastic syndrome, management of low grade gliomas, and identifying pitfalls in neuro-oncology imaging.

"The John Theurer Cancer Center is committed to helping our staff and the tri-state area neuro-oncology medical community stay up-to -date with the latest medical advancements through educational programs," said Mark Pascal, M.D., Co- Chief, Neuro-Oncology, John Theurer Cancer Center.

The program will feature neuro-oncology experts from world-renowned institutions such as Memorial Sloan-Kettering Cancer Center, Roswell Park Cancer Institute and University of Virginia Health System. Featured speakers include:

  • Jerome Posner, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY
  • Dheerendra Prasad, M.D., Roswell Park Cancer Institute, Buffalo, NY
  • David Schiff, M.D., University of Virginia Health System, Charlottesville, VA
  • Andrei Holodny, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY

"It is part of our mission at the John Theurer Cancer Center to promote research and innovation through education," said Andrew L. Pecora, M.D., C.P.E., F.A.C.P., Chief Innovations Officer and Professor and Vice President of Cancer Services at the John Theurer Cancer Center. "The Neuro-Oncology Symposium is just one example of the superior continuing medical education programs we offer throughout the year."

This program is open to the public, but is designed for neurologists, neurosurgeons, medical oncologists, radiation oncologists, internists, primary care physicians, neuropsychologists, other physicians and healthcare providers. Hackensack University Medical Center designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s). The program will be held at the John Theurer Cancer Center at Hackensack University Medical Center, 92 Second Street, Hackensack, NJ in the #2 conference room.

This event is complimentary, however registration is required. To register, please contact Maryann V. Lederhilger at (551) 996-1162 or For updates and additional information, please visit


Contact: Jaymie DeGaetano
John Theurer Cancer Center

Related medicine news :

1. John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
2. The MMRF and John Theurer Cancer Center to host patient symposium
3. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
4. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
5. Oncology basic research director at John Theurer Cancer Center continues transplantation research
6. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
7. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
8. John Theurer Cancer Center to present innovative research at 2 surgical meetings
9. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
10. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
11. The John Theurer Cancer Center recognizes medical physics team for safety track record
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology: